IL6 and TNFα production in HCQ-treated patients
| . | Baseline . | 6 mo of HCQ . | 2 mo after HCQ interruption . | P . |
|---|---|---|---|---|
| LPS-stimulated PBMCs, % positive | ||||
| IL-6+CD14+ cells | 63.94 ± 5.91 | 42.63 ± 4.95 | 62.00 ± 5.10 | NS |
| TNFα+CD14+ cells | 53.71 ± 3.87 | 40.56 ± 5.43 | 51.90 ± 4.10 | NS |
| ssRNA-stimulated PBMCs, % positive | ||||
| IL-6+CD14+ cells | 67.76 ± 3.70 | 58.99 ± 4.39 | 37.00 ± 5.00 | 6 mo vs 2 mo: 0.007 |
| TNFα+CD14+ cells | 78.30 ± 3.20 | 64.42 ± 3.32 | 69.39 ± 5.10 | Baseline vs 6 mo: 0.038 |
| Env + gag–stimulated PBMCs, % positive | ||||
| IL-6+CD4+ cells | 1.71 ± 0.94 | 1.62 ± 0.58 | 3.37 ± 1.70 | NS |
| TNFα+CD4+ cells | 3.37 ± 1.70 | 2.66 ± 0.39 | 5.07 ± 1.24 | NS |
| Plasma cytokine concentrations, pg/mL | ||||
| IL-6 | 5.78 ± 2.66 | 2.42 ± 0.80 | 1.18 ± 0.21 | Baseline vs 2 mo: 0.048 |
| TNFα | 8.55 ± 1.46 | 8.85 ± 2.42 | 27.41 ± 7.78 | NS |
| . | Baseline . | 6 mo of HCQ . | 2 mo after HCQ interruption . | P . |
|---|---|---|---|---|
| LPS-stimulated PBMCs, % positive | ||||
| IL-6+CD14+ cells | 63.94 ± 5.91 | 42.63 ± 4.95 | 62.00 ± 5.10 | NS |
| TNFα+CD14+ cells | 53.71 ± 3.87 | 40.56 ± 5.43 | 51.90 ± 4.10 | NS |
| ssRNA-stimulated PBMCs, % positive | ||||
| IL-6+CD14+ cells | 67.76 ± 3.70 | 58.99 ± 4.39 | 37.00 ± 5.00 | 6 mo vs 2 mo: 0.007 |
| TNFα+CD14+ cells | 78.30 ± 3.20 | 64.42 ± 3.32 | 69.39 ± 5.10 | Baseline vs 6 mo: 0.038 |
| Env + gag–stimulated PBMCs, % positive | ||||
| IL-6+CD4+ cells | 1.71 ± 0.94 | 1.62 ± 0.58 | 3.37 ± 1.70 | NS |
| TNFα+CD4+ cells | 3.37 ± 1.70 | 2.66 ± 0.39 | 5.07 ± 1.24 | NS |
| Plasma cytokine concentrations, pg/mL | ||||
| IL-6 | 5.78 ± 2.66 | 2.42 ± 0.80 | 1.18 ± 0.21 | Baseline vs 2 mo: 0.048 |
| TNFα | 8.55 ± 1.46 | 8.85 ± 2.42 | 27.41 ± 7.78 | NS |
Data are presented as mean ± SE.
NS indicates not significant.